Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report by Angelika Bezan et al.
Bezan et al. BMC Cancer 2013, 13:618
http://www.biomedcentral.com/1471-2407/13/618CASE REPORT Open AccessSystemic effect of catumaxomab in a patient with
metastasized colorectal cancer: a case report
Angelika Bezan1, Florian Hohla1*, Thomas Meissnitzer2 and Richard Greil1Abstract
Background: Catumaxomab, the first anti-EpCAM antibody, was approved in 2009 for the treatment of malignant
ascites in cancer patients with EpCAM positive tumors. We consider this case of interest as treatment with catumax-
omab not only prolonged the puncture-free interval but also showed a systemic effect in a patient with metasta-
sized colorectal cancer by regression of a pulmonary metastasis.
Case presentation: We describe the case of a 78 year old patient initially diagnosed with locally advanced colon
cancer and one synchronous liver metastasis in September 2010 who was treated by hemicolectomy and
simultaneous atypical liver resection. During adjuvant chemotherapy the patient developed a peritoneal
carcinomatosis with ascites in March 2011. Palliative chemotherapy was not well tolerated and therefore refused by
the patient. Because of disease progression in June 2011 with one pulmonary metastasis and clinically predominant
ascites an immunotherapy with intraperitoneal catumaxomab was started in December 2011. After treatment with
catumaxomab a puncture free survival of 12 months as well as a regression of the pulmonary lesion was achieved
until January 2013.
Conclusion: This case suggests that treatment with catumaxomab does not only improve quality of life by local
suppression of malignant ascites but also might have a systemic antitumor effect.
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Metachronous peritoneal carcinomatosis (PC) has been
reported in 4-12% of patients with colorectal cancer
(CRC) [1]. According to the EVOCAPE 1 study median
overall survival for patients with PC from CRC is 6.9
months, depending on TNM stage, size and distribution
of peritoneal nodules and the presence of ascites [2].
Modern systemic chemotherapy as well as cytoreductive
surgery and hyperthermic intraperitoneal (i.p.) chemo-
therapy are current treatment options for selected pa-
tients to prolong overall survival [3]. Malignant ascites,
which is caused by the intraperitoneal spread of tumor
cells, has an immense impact on the quality of life due to
its symptoms and frequent recurrence [4]. Peritoneal tumor
cells of CRC origin frequently overexpress the epithelial
cell-adhesion molecule (EpCAM) [5]. Catumaxomab,* Correspondence: f.hohla@salk.at
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reproduction in any medium, provided the orwhich has been approved for the treatment of malignant
ascites [6], has antigen-binding sites to epithelial tumor
cells via EpCAM and to T-cells via CD3. With the Fc
domain catumaxomab activates accessory cells resulting
in a pro-inflammatory response leading to an immuno-
logic antitumor effect [7].
We report on a 78 years old patient with peritoneal and
pulmonary metastasized CRC. We consider this case of
interest as treatment with i.p. Infusions of catumaxomab
not only prolonged the puncture-free interval but also
showed a systemic effect by regression of a pulmonary
metastasis.
Case presentation
In September 2010 a 78 years old man was diagnosed
with an adenocarcinoma of the right-sided colon. Initial
staging by abdominal and pulmonary CT revealed a lesion
in the right-sided colon penetrating the visceral peritoneum
with infiltration of the abdominal wall (cT4b) and a single
metastatic lesion in the liver, in segment VII, with a dia-
meter of 1.5 cm (M1a) according to a stage IVA disease.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Contrast-enhanced computed tomography scan of the
abdomen showing ascites (big arrow) and peritoneal nodules
(small arrows) in March 2011.
Figure 2 Contrast-enhanced computed tomography scan of the chest
(a) A 3.3 × 2.8 cm mass (big arrow) in the left lung and (b) ascites in all 4
(small arrows).
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ultaneous atypical resection of the single liver metastasis
adjuvant chemotherapy (CTX) with capecitabine and
oxaliplatin was started. After 5 cycles of adjuvant CTX
the patient complained about a considerable increase of
his abdominal girth. An abdominal CT in March 2011
yielded peritoneal nodules and ascites (Figure 1).
After confirmation of a mutated K-RAS gene a pallia-
tive first line CTX with capecitabine and irinotecan in
combination with bevacizumab was started. However,
treatment was interrupted right after the first cycle be-
cause of an episode with neutropenic fever and resump-
tion of CTX was refused by the patient until June 2011.
CT imaging in June 2011 showed a disease progression
with a new solitary pulmonary lesion with a diameter of
3.3 × 2.8 cm (Figure 2a) and ascites in all 4 quadrants of
the abdomen (Figure 2b). As the patient refused biopsyand abdomen showing disease progression in June 2011.
quadrants of the abdomen (big arrow) and peritoneal nodules
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that the lung lesion was radiological consistent with a pul-
monary metastasis a biopsy was not performed. Tumor
markers CEA and CA 19.9 were within normal range at
the time of diagnosis and during the whole course of dis-
ease. Clinically, the amount of ascites was increasing and
required abdominal punctures on a weekly basis. There-
fore the first line CTX with capecitabine, irinotecan and
bevacizumab was reinitiated. Despite administration of
granulocyte colony stimulation factor another episode
of neutropenic fever occurred and CTX was discontinued
after a total of 3 cycles in August 2011. As the patient
refused to receive any further CTX and because of ascites
being the predominant clinical symptom an immunotherapyFigure 3 Contrast-enhanced computed tomography scan of the chest
(a) Partial response of the pulmonary lesion (1.8 × 1.1 cm, big arrow) and (
amount of ascites.with i.p. catumaxomab was started in December 2011 (4
consecutive i.p. infusions of catumaxomab on days 0, 3, 7
and 10 at increasing doses of 10, 20, 50 and 150 μg).
Treatment was well tolerated without any side effects.
Surveillance by CT scan in April, July and October 2012
showed a partial response of the pulmonary lesion and no
paracentesis was necessary until January 2013 (Figure 3a
and b). While the pulmonary lesion showed a further re-
gression in size and could finally only be detected as a scar
(Figure 4a), a CT scan in January 2013 showed a progres-
sive peritoneal disease with ascites and a consecutive
hydronephrosis III° of the right kidney (Figure 4b). As the
patient still refused any further CTX we decided to restart
i.p. treatment with catumaxomab in January 2013.and abdomen after treatment with catumaxomab in July 2012.
b) regression of peritoneal carcinomatosis (small arrows) with less
Figure 4 Contrast-enhanced computed tomography scan of the chest and abdomen in January 2013. (a) The pulmonary lesion can only
be detected as a scar (big arrow). (b) Recurrent ascites (big arrows) and peritoneal nodules (small arrows).
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Peritoneal carcinomatosis (PC) is one manifestation of
metastatic CRC and is associated with a poor prognosis
[3]. Few studies have been published describing the effec-
tiveness of systemic chemotherapy in patients with PC.
The results invariably show a disappointing response to
systemic treatment and a poor prognosis compared to
other metastatic sites [2,3]. CRC frequently overexpresses
EpCAM [5]. Overexpression of EpCAM has been associ-
ated with dismal prognosis in other tumor entities, such
as gallbladder cancer, ovarian cancer and pancreatic can-
cer [8-10]. Catumaxomab, the first anti-EpCAM antibody,
was approved in 2009 for the treatment of malignant asci-
tes in cancer patients with EpCAM positive tumors [6].
This prospective randomized phase II/III trial showed a
significantly prolonged median puncture free survival with
catumaxomab (46 days) compared to paracentesis alone(11 days) in the pooled population. Although the study
was not powered to detect a difference in overall survival,
OS showed a positive trend for the catumaxomab group
and was significantly prolonged in patients with gastric
cancer patients compared to paracentesis alone (71 versus
44 days;p = 0.0313). Interestingely, in our case report treat-
ment with catumaxomab not only extended puncture free
survival by 12 months but also caused a regression of the
pulmonary metastasis suggesting a possible systemic ef-
fect. So far an extraperitoneal effect of catumaxomab has
never been described in a patient with colorectal cancer
and was reported for a patient with ovarian cancer and
breast cancer [11,12]. A possible explanation for this sys-
temic effect on tumor cells might be that catumaxomab is
absorbed by lymphatics in the peritoneum and reaches
the circulation. Low systemic catumaxomab levels (<1%)
could be measured after i.p. infusion in nine out of
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variability [13]. Thus, an inverse correlation between
tumor burden and systemic antibody bioavailability of
catumaxomab was demonstrated in patients and in a de-
fined mouse model [13]. The bioavailability of catumax-
omab significantly declined in mice with higher tumor
load. In the pivotal trial of Heiss et al. efficacy of catu-
maxomab was higher in patients without metastasis
compared to patients with higher metastasis [6]. There-
fore, in our patient a lower tumor burden might have
resulted in higher plasma levels of catumaxomab. As
blood samples have not been taken this determinant re-
mains speculative. Furthermore an induction of anti-
tumor specific T-lymphocytes that has been described
after intraperitoneal administration of catumaxomab
might be causative for its antiproliferative effect on distant
metastasis [14]. Thus, in 5 out of 9 patients intraperitoneal
administration of trifunctional antibodies such as catu-
maxomab induced a significant increase of tumor reactive
CD4+/CD8+ T-lymphocytes with a prolonged survival. As
catumaxomab is a nonhumanized chimeric antibody de-
rived from mouse/rat IgG it is immunogenic when ad-
ministered to humans. Thus, the development of human
antimouse antibodies (HAMAs), which are associated
with beneficial humoral effects and prolonged survival,
could be detected in up to 95% of patients treated with
catumaxomab [6]. In a post hoc analysis the correlation
between the detection of HAMAS and clinical outcome
was analyzed [15]. Patients who developed HAMAs after
catumaxomab showed significant improvement in punc-
ture-free survival, time to next puncture and OS [15]. Un-
aware of the impressive clinical outcome, no blood
samples were taken from our patient in order to detect
HAMAs. In the study of Heiss et al. the primary study ob-
jective was puncture free survival. Additionally the num-
ber of intraperitoneal tumor cells was counted before and
after intraperitoneal administration of catumaxomab but
no imaging method was used to assess the response to
catumaxomab [6]. In the randomized phase IIa study by
Baumann et al., response to catumaxomab in patients with
platinum-resistant or –refractory epithelial ovarian cancer
was assessed according to the Response Evaluation Cri-
teria in Solid Tumors (RECIST) guidelines for the first
time [16]. The study revealed that catumaxomab had only
modest activity in platinum-resistant ovarian cancer with
an overall response rate of 28% in the high- dose treat-
ment arm (10,20,50 and 100 μg) compared to 5% in the
low-dose group (10,10,10 and 10 μg) on days 0,3,7 and 10.
Taken together, our observation suggests that catu-
maxomab might have a relevant systemic effect on
cancer cells and therefore might improve the prognosis
of patients with EpCAM-positive tumors. Further in-
vestigations to prove and to further explain this sys-
temic effect of catumaxomab are warranted.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the editor of this journal.
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